Medicare Part B Coverage for In-Office Osteoporosis Treatments
When lifestyle changes and calcium supplements cannot stabilize bone loss, physicians prescribe medical therapies. Medicare Part B covers osteoporosis medications administered by a healthcare professional in an outpatient clinic or physician office.
Common Part B injectables include Prolia (denosumab), Evenity (romosozumab), and Reclast (zoledronic acid). Denosumab injections occur every six months, whereas zoledronic acid is an annual intravenous infusion.
CMS billing guidelines also cover newer Food and Drug Administration (FDA) approved denosumab biosimilars, including Jubbonti and Ospomyv. These biosimilars provide comparable biological effectiveness at potentially lower costs.
Out-of-Pocket Part B Expenses
Unlike preventive DEXA scans, Part B osteoporosis therapies carry out-of-pocket costs. You must first meet your annual Part B deductible before Medicare pays its share.
In 2026, the official Part B deductible is $283, with a standard monthly premium of $202.90. The Medicare Trustees Report projects that the Part B deductible will reach $292 in 2027, with a $209.50 monthly premium.
After satisfying your Part B deductible, you pay 20% of the Medicare-approved amount for the drug and its administration. Supplemental policies like Medigap often cover this 20% coinsurance entirely.
Special Home Health Injection Benefit
Medicare provides specialized home health injection coverage for postmenopausal women who cannot leave home without assistance. This benefit requires a doctor to certify that you suffered a bone fracture related to postmenopausal osteoporosis.
Your physician must also certify that you cannot self-inject and lack caregivers able and willing to help. Under this program, the visiting home health nurse costs you $0.
However, you remain responsible for the standard Part B deductible and the 20% coinsurance on the injectable medication itself, while Medicare covers the administrative visit.
